EXECUTIVE ENGAGEMENTS
OUTREACH
8934
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1251
Interactions with Platform & by Email
PARTICIPANTS
268
Unique # Participated
VALIDATIONS
121
Responses Validated*
COMPETITORS
43
Responses Validated*
BRANDS
989
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
126
PAGES
199
EDITION
9
PRICE
USD $4950
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Protein Therapeutics estimated at US$164.2 Billion in the year 2020, is projected to reach a revised size of US$233.1 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$122.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Insulin segment is readjusted to a revised 5.4% CAGR for the next 7-year period.
The Protein Therapeutics market in the U.S. is estimated at US$48.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
In the global Fusion Protein segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$15 Billion in the year 2020 will reach a projected size of US$20.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$26.7 Billion by the year 2027.
SELECT PLAYERS
Abbott Laboratories; Amgen, Inc.; AstraZeneca PLC; Baxter International, Inc.; Biogen, Inc.; Boehringer Ingelheim International GmbH; Chugai Pharmaceutical Co., Ltd.; Diasome Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Genentech, Inc.; Generex Biotechnology Corporation; GeneScience Pharmaceuticals Co., Ltd.; Hualan Biological Engineering, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Merck Serono SA; Novo Nordisk A/S; Oramed Pharmaceuticals Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Application (Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications) » Product Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Other Product Types)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Fusion Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Fusion Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Fusion Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Interferon by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hematological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hormonal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Protein Therapeutics by Product Type - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Protein Therapeutics by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 43 |
The U.S. Economy is Reinventing Itself to Weather Economic Storms.
Here's An Analytical Window into the Changing Opportunities.
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com